Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7

Abstract

Estrogen receptor (ER) α plays an important role in the proliferation and progression of breast cancer. In order to explore the function of wild-type ERβ (ERβ1) and its variant form, ERβcx/β2, stable transformants of ERα-positive breast cancer MCF7 cells with ERβ1 or ERβcx/β2 expression vector were established. Constitutive expression of ERβ1 or ERβcx/β2 reduced the S phase population of the cell cycle in dish culture and the number of colonies in an anchorage-independent assay. DNA–protein complexes of ERE with nuclear extracts from ERβ1 transformants were observed in the electrophoretic mobility shift assay, while no complex was observed for ERβcx/β2 transformants. Reporter gene assay using estrogen-responsive element (ERE)-luciferase showed less responsiveness to estrogen in these transformants compared with parental cells. Endogenous mRNA expression of two known estrogen-responsive genes, cathepsin D and IGFBP4, was weakly induced by estrogen in ERβ1 and ERβcx/β2 transformants compared with parental cells. A comprehensive gene expression analysis using our custom-made cDNA microarray showed that MCF7 and ERβ1 transformants had a similar gene expression profile, whereas ERβcx/β2 showed a distinct profile from others. These results indicate that ERβ1 and ERβcx/β2 inhibit ERα function differently in MCF7 cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M and Liaudet-Coopman E . (2002). Oncogene, 21, 5951–5955.

  • Bièche I, Parfait B, Laurendeau I, Girault I, Vidaud M and Lidereau R . (2001). Oncogene, 20, 8109–8115.

  • Btist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowen KH . (1986). J. Biol. Chem., 261, 15544–15549.

  • Chu S, Mamers P, Burger HG and Fuller PJ . (2000). J. Clin. Endocrinol. Metab., 85, 1200–1205.

  • Clemmons DR, Camacho-Hubner C, Coronado E and Osborne CK . (1990). Endocrinology, 127, 2679–2686.

  • Cowley SM and Parker MG . (1999). J. Steroid Riochem., Mol. Biol., 69, 165–175.

  • Dotzlaw H, Leygue E, Watson P and Murphy L . (1997). J. Clin. Endocrinol. Metab., 82, 2371–2374.

  • Early Breast Cancer Trialists' Collaborative Group. (1998). Lancet, 351, 1451–1467.

  • Eguchi H, Suga K, Saji H, Toi M, Nakachi K and Hayashi S-I . (2000). Cell Death Differ., 7, 439–446.

  • Eisen MB, Spellman PT, Brown PO and Botstein D . (1998). Proc. Natl. Acad. Sci. USA, 95, 14863–14868.

  • Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M and Gustafsson J-Å . (1997). J. Clin. Endocrinol. Metab., 82, 4258–4265.

  • Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S and Messori A . (1997). Br. J. Cancer, 76, 661–666.

  • Figueroa JA, Jackson JG, McGuire WL, Krywicki RF and Yee D . (1993). J. Cell Biochem., 52, 196–205.

  • Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL and Klijn JG . (1999). Br. J. Cancer, 79, 300–307.

  • Fujimura T, Takahashi S, Urano T, Ogawa S, Ouchi Y, Kitamura T, Muramatsu M and Inoue S . (2001). Biochem. Biophys. Res. Commun., 289, 692–699.

  • Hall JM and McDonnell DP . (1999). Endocrinology, 140, 5566–5578.

  • Honma Y, Yamamoto-Yamaguchi Y and Kanatani Y . (1999). Br. J. Cancer, 80, 96–100.

  • Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R and Hayashi S . (2002). J. Mol. Endocrinol., 29, 175–192.

  • Iwao K, Miyoshi Y, Egawa C, Ikeda N and Noguchi S . (2000). Int. J. Cancer, 88, 733–736.

  • Jarvinen TAH, Pelto-Huikko M, Holli K and Isola J . (2000). Am. J. Pathol., 156, 29–35.

  • Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson J-Å . (1996). Proc. Natl. Acad. Sci. USA, 93, 5925–5930.

  • Lazennec G, Bresson D, Lucas A, Chauveau C and Vignon F . (2001). Endocrinology, 142, 4120–4130.

  • Leygue E, Dotzlaw H, Watson PH and Murphy LC . (1998). Cancer Res., 58, 3197–3201.

  • Leygue E, Dotzlaw H, Watson PH and Murphy LC . (1999). Cancer Res., 59, 1175–1179.

  • Locker GY . (1998). Cancer Treat. Rev., 24, 221–240.

  • Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM and Willson TM . (1998). Biochem. Biophys. Res. Commun., 247, 75–78.

  • NIH Consensus Development Conference, Steroid receptors in breast cancer. Bethesda, Maryland, June 27–29, 1979 (1980). Cancer, 46, 2759–2963.

  • Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y and Muramatsu M . (1998). Nucleic Acids Res., 26, 3505–3512.

  • Omoto Y, Iwase H, Iwata H, Hara Y, Toyama T, Ando Y and Kobayashi S . (2000). Breast Cancer, 7, 27–31.

  • Omoto Y, Inoue S, Iwase H, Yamashita H, Toyama T, Hara Y, Ogawa S, Muramatsu M and Kobayashi S . (2001a). Cancer Lett., 163, 207–212.

  • Omoto Y, Kobayashi Y, Nishida K, Eiju T, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson J-Å and Hayashi S-I . (2001b). Biochem. Biophysic. Res. Commun., 285, 340–347.

  • Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson J-Å and Iwase H . (2002). Eur. J. Cancer, 38, 380–386.

  • Owens PC, Gill PG, De Young NJ, Weger MA, Knowles SE and Moyse KJ . (1993). Biochem. Biophys. Res. Commun., 193, 467–473.

  • Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS . (1997). Science, 277, 1508–1510.

  • Peng B, Lu B, Leygue E and Murphy LC . (2003). J. Mol. Endocrinol., 30, 13–29.

  • Pettersson K, Grandien K, Kuiper GGJM and Gustafsson J-Å . (1997). Mol. Endocrinol., 11, 1486–1496.

  • Pratt SE and Pollak MN . (1993). Cancer Res., 53, 5193–5198.

  • Rochefort H, Capony F, Garcia M, Cavailles V, Freiss G, Chambon M, Morisset M and Vignon F . (1987). J. Cell Biochem., 35, 17–29.

  • Rochefort H . (1992). Eur. J. Cancer, 28A, 1780–1783.

  • Russell KS, Haynes MP, Sinha D, Clerisme E and Bender JR . (2000). Proc. Natl. Acad. Sci. USA, 97, 5930–5935.

  • Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J-Å and Toi M . (2002). Cancer Res., 62, 4849–4853.

  • Speirs V, Malone C, Walton DS, Kerin MJ and Atkin SL . (1999). Cancer Res., 59, 5421–5424.

  • Tanimoto K, Eguchi H, Yoshida T, Hajiro-Nakanishi K and Hayashi S . (1999). Nucleic Acids Res., 27, 903–909.

  • Toi M, Bisknell R and Harris AL . (1992). Cancer Res., 52, 275–279.

  • Tong D, Schuster E, Seifert M, Czerwenka K, Leodolter S and Zellinger R . (2002). Breast Cancer Res. Treat., 71, 249–255.

  • Vickers PJ, Dickson RB, Shoemaker R and Cowen KH . (1988). Mol. Endocrinol., 2, 886–892.

  • Vladusic EA, Hornby AE, Guerra-Vladusic FK and Lupu R . (1998). Cancer Res., 58, 210–214.

  • Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J and Lupu R . (2000). Oncol. Rep., 7, 157–167.

Download references

Acknowledgements

We thank Ms Akiyo Yamashita for her excellent technical support. This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, for Scientific Research Expenses for Health and Welfare Programs and the Foundation for the Promotion of Cancer Research, and by the Second-Term Comprehensive 10-Year Strategy for Cancer Control.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shin-ichi Hayashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Omoto, Y., Eguchi, H., Yamamoto-Yamaguchi, Y. et al. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 22, 5011–5020 (2003). https://doi.org/10.1038/sj.onc.1206787

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206787

Keywords

This article is cited by

Search

Quick links